DNER and neoplasm: For one, we observed that whereas futibatinib was brain penetrant (14% brain:plasma ratio) in mice, birabresib was not as strongly penetrant (1% brain penetrant in non-tumor bearing, 6% penetrant in tumor-bearing mice), and therefore it is possible that not enough BET inhibitor reached the tumor cells within the brain (Fig. 4c).